Show simple item record

dc.contributor.authorChow, EPF
dc.contributor.authorMaddaford, K
dc.contributor.authorHocking, JS
dc.contributor.authorBradshaw, CS
dc.contributor.authorWigan, R
dc.contributor.authorChen, MY
dc.contributor.authorHowden, BP
dc.contributor.authorWilliamson, DA
dc.contributor.authorFairley, CK
dc.date.accessioned2020-11-26T23:34:17Z
dc.date.available2020-11-26T23:34:17Z
dc.date.issued2020-11-09
dc.identifierpii: 10.1038/s41598-020-76184-1
dc.identifier.citationChow, E. P. F., Maddaford, K., Hocking, J. S., Bradshaw, C. S., Wigan, R., Chen, M. Y., Howden, B. P., Williamson, D. A. & Fairley, C. K. (2020). An open-label, parallel-group, randomised controlled trial of antiseptic mouthwash versus antibiotics for oropharyngeal gonorrhoea treatment (OMEGA2). SCIENTIFIC REPORTS, 10 (1), https://doi.org/10.1038/s41598-020-76184-1.
dc.identifier.issn2045-2322
dc.identifier.urihttp://hdl.handle.net/11343/252272
dc.description.abstractNew treatments for oropharyngeal gonorrhoea are required to address rising antimicrobial resistance. We aimed to examine the efficacy of a 14-day course of mouthwash twice daily compared to standard treatment (antibiotic) for the treatment of oropharyngeal gonorrhoea. The OMEGA2 trial was a parallel-group and open-labelled randomised controlled trial among men with untreated oropharyngeal gonorrhoea that was conducted between September 2018 and February 2020 at Melbourne Sexual Health Centre in Australia. Men were randomised to the intervention (rinsing, gargling and spraying mouthwash twice daily for 14 days) or control (standard treatment) arm and followed for 28 days. Participants in both arms were advised to abstain from sex and kissing with anyone for 14 days after enrolment. Oropharyngeal swabs were collected at baseline, Day 14 and Day 28 and tested for Neisseria gonorrhoeae by nucleic acid amplification test (NAAT) and culture. The primary outcome was the detection of oropharyngeal N. gonorrhoeae by NAAT at Day 14 after treatment. This trial was registered on the Australian and New Zealand Clinical Trials Registry (ACTRN12618001380280). This trial stopped early due to a high failure rate in the mouthwash arm. Twelve men were randomly assigned to either mouthwash (n = 6) or standard treatment (n = 6). Of the 11 men who returned at Day 14, the cure rate for oropharyngeal gonorrhoea in the mouthwash arm was 20% (95% CI 1-72%; 1/5) and in the standard treatment arm was 100% (95% CI 54-100%; 6/6). A 14-day course of mouthwash failed to cure a high proportion of oropharyngeal gonorrhoea cases.
dc.languageEnglish
dc.publisherNATURE RESEARCH
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleAn open-label, parallel-group, randomised controlled trial of antiseptic mouthwash versus antibiotics for oropharyngeal gonorrhoea treatment (OMEGA2)
dc.typeJournal Article
dc.identifier.doi10.1038/s41598-020-76184-1
melbourne.affiliation.departmentMicrobiology and Immunology
melbourne.affiliation.departmentMelbourne School of Population and Global Health
melbourne.source.titleScientific Reports
melbourne.source.volume10
melbourne.source.issue1
melbourne.source.pages19386-
melbourne.identifier.nhmrc1136117
melbourne.identifier.nhmrc1105905
melbourne.identifier.nhmrc1174555
dc.rights.licenseCC BY
melbourne.elementsid1479763
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652834
melbourne.contributor.authorWilliamson, Deborah
melbourne.contributor.authorHowden, Benjamin
melbourne.contributor.authorHocking, Jane
melbourne.contributor.authorChow, Eric
melbourne.contributor.authorBradshaw, Catriona
melbourne.contributor.authorChen, Marcus
dc.identifier.eissn2045-2322
melbourne.identifier.fundernameidNHMRC, 1136117
melbourne.identifier.fundernameidNHMRC, 1105905
melbourne.identifier.fundernameidNHMRC, 1174555
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record